IL33 and graft versus host disease: In the current studies, we provide mechanistic insights into IL-33–mediated CD4+ T cell immunobiology after alloHCT and build on our past observation that IL-33 is a clinically relevant, recipient-derived DAMP that drives lethal GVHD (29).